dannomura.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

Cool paper from Cravatt lab on an allosteric cyclin E-CDK2 site mapped by paralog hopping with covalent probes www.nature.com/articles/s41...

submitted 3 days ago • 0 comments

New @biorxivpreprint.bsky.social from our lab, Maimone lab, and @novartis.bsky.social on a covalent destabilizing degrader of myc that acts through stereoselective targeting of an IDR C203 in MYC! Congrats to first authors Hannah Rosen and Kelvin Li! www.biorxiv.org/content/10.1...

submitted 4 days ago • 1 comment

www.science.org/content/arti...

submitted 5 days ago • 1 comment

Cool paper from Matt Bogyo’s lab: pubs.acs.org/doi/10.1021/...

submitted 5 days ago • 0 comments

www.science.org/content/arti...

submitted 5 days ago • 0 comments

Headed to Boston to give a talk about our latest research at MIT Biological Engineering hosted by Angela Koehler and then visit my friends at @novartis.bsky.social ! Look out for a new Biorxiv coming out of our lab imminently on a new covalent MYC degrader! be.mit.edu/our-communit...

submitted 5 days ago • 0 comments

After an awesome Targeted Protein Degradation Keystone meeting last week, happy to be back @ethzurich.bsky.social this week to give a talk about our latest work alongside the great @songlin1.bsky.social ! chab.ethz.ch/en/research/...

submitted 7 days ago • 0 comments

Thank you @nplb.bsky.social for speaking out in defense of patients, the US economy and our citizenship. Encouraged to see biopharma and investors among patients, health care providers, scientists and policy makers. www.nopatientleftbehind.org/defending-th...

submitted 9 days ago • 0 comments

www.sfchronicle.com/politics/joe...

submitted 9 days ago • 0 comments

New York Times article now up on Federal Register stuff. www.nytimes.com/2025/02/21/s... 1/n

submitted 10 days ago • 17 comments

www.nytimes.com/2025/02/21/s...

submitted 10 days ago • 0 comments

"Even NIH officers don’t know what will happen next." In our latest @science.org Working Life essay, an assistant professor expresses frustration with stalls at NIH and asks: "Will my grants ever be reviewed?" @vjrp.bsky.social www.science.org/content/arti...

submitted 10 days ago • 3 comments

A US Senator Joins the Fray. Thank you @murray.senate.gov ! More of this, please! www.murray.senate.gov/senator-murr...

submitted 10 days ago • 9 comments

"These kinds of shocks are going to lead to a mass exodus … for minorities in particular.” For my latest @science.org story, I spoke with early career researchers who have been affected by the federal upheaval and are concerned about what it means for their future. www.science.org/content/arti...

submitted 10 days ago • 21 comments

I agree. It seems extremely unlikely that they are trying to get grants flowing again. One of my concerns is that they may be hoping to delay things enough that NIH will not have time to get appropriated funds issued by September 30th, the end of the fiscal year. 1/n

submitted 11 days ago • 5 comments

www.statnews.com/2025/02/19/t...

submitted 11 days ago • 0 comments

www.nature.com/articles/d41...

submitted 11 days ago • 0 comments

As @jeremymberg.bsky.social correctly assessed at the time, the NIH memo that slashed overhead rates came from Trump/Musk, not anyone within the organization.

submitted 12 days ago • 7 comments

Cool preprint from Ben Cravatt and Phil Baran: www.biorxiv.org/content/10.1...

submitted 11 days ago • 0 comments

www.thetransmitter.org/funding/fede...

submitted 12 days ago • 1 comment

Graduate student admissions paused at Vanderbilt 😟 vanderbilthustler.com/2025/02/15/g...

submitted 13 days ago • 7 comments

I’m a standing member on the Chemical Biology and Probes (CBP) NIH study section that was supposed to meet tomorrow. It just got postponed this afternoon with a date yet to be determined….

submitted 12 days ago • 3 comments

New @biorxivpreprint.bsky.social preprint from Amgen induced proximity group and @dannomura.bsky.social lab just posted that describes Covalent Destabilizing Degrader of AR and AR-V7 in Androgen-Independent Prostate Cancer Cells. Read on for an overview 1/7 www.biorxiv.org/content/10.1...

submitted 13 days ago • 1 comment

Our latest BioRxiv by @cmzammit.bsky.social, Cory Nadel, @pottslab.bsky.social on a covalent destabilizing degrader against AR & AR-V7 in prostate cancer that targets an IDR C125 to destabilize, inhibit, and degrade TF! Thanks to @amgen.bsky.social, MTI, Berkeley MCB/Chemistry, NCI, TMFCR, and NSF!

submitted 15 days ago • 0 comments

www.nytimes.com/interactive/...

submitted 16 days ago • 1 comment

Today in @nature.com we share our back-to-back stories with Ning Zheng’s lab revealing chemical-genetic convergence between a molecular glue degrader & E3 ligase cancer mutations. 1/5

submitted 19 days ago • 5 comments

popular.info/p/trump-main...

submitted 20 days ago • 0 comments

endpts.com/judge-halts-...

submitted 21 days ago • 0 comments

www.statnews.com/2025/02/10/n...

submitted 21 days ago • 1 comment

Honored to be selected as the new editor-in-chief for Molecular Cancer Therapeutics! I look forward to working with the cancer therapeutics community! www.aacr.org/about-the-aa...

submitted 21 days ago • 8 comments

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS or other (non-LCH) dendritic or histiocytic sarcomas cases.

submitted 23 days ago • 86 comments

Exciting paper from Xiaoyu Zhang's lab at Northwestern: pubs.acs.org/doi/full/10....

submitted 24 days ago • 0 comments

www.statnews.com/2025/02/07/n...

submitted 24 days ago • 0 comments

1. Today the NIH director issued a new directive slashing overhead rates to 15%. I want to provide some context on what that means and why it matters. grants.nih.gov/grants/guide...

submitted 24 days ago • 270 comments

NIH indirects just got capped to 15 %… grants.nih.gov/grants/guide...

submitted 24 days ago • 1 comment

www.science.org/content/blog...

submitted 25 days ago • 0 comments

Great to be back at Yale! Looking forward to my visit tomorrow to the Department of Chemistry and giving a talk about our latest research! Thanks Stacy Malaker for hosting! events.yale.edu/event/chemic...

submitted 34 days ago • 0 comments

Awesome to be back at University of Chicago! Excited to see everyone and give a talk about our latest work! Thanks @chembiobryan.bsky.social for hosting!

submitted 39 days ago • 1 comment

Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring | Science | AAAS www.science.org/content/arti...

submitted 40 days ago • 0 comments

Mass spec/proteomics chempostdoc in the Ferguson lab, UCSD, La Jolla, CA chemsky 🧪 ⚗️ jobrxiv.org/job/universi...

submitted 47 days ago • 0 comments

New @biorxivpreprint.bsky.social from Lycia TX: www.biorxiv.org/content/10.1...

submitted 49 days ago • 0 comments

Sunday morning ☕ reading: cool paper from using BioE3 to dissect CRBN targeting. One surprise - pomalidomide doesn't just add neosubstrates, also seems to decrease ubiquitination of CRBN's natural targets. New insight into indirect effects of new modalities. www.biorxiv.org/content/10.1...

submitted 50 days ago • 0 comments

Cool partnership between Lilly and a16z: www.statnews.com/2025/01/10/e...

submitted 52 days ago • 0 comments

Great review on covalent drugging of undruggable targets from Itaru Hamachi: pubs.acs.org/doi/10.1021/...

submitted 52 days ago • 0 comments

Reflecting on 20 years of progress Sarah E. O’Connor, Benjamin F. Cravatt and Chengqi Yi talk about the major changes in chemical biology, the advances that have most affected their research, and their thoughts about the important questions facing chemical biologists. rdcu.be/d5Sm0

submitted 52 days ago • 0 comments

Thank you to Eric Gomez for introducing TCG labs Soleil to Molecular Therapeutics faculty at @ucberkeleyofficial.bsky.social today!

submitted 53 days ago • 0 comments

Congrats to ⁦‪Frontier Medicines‬⁩ on their covalent p53 Y220C activator FMC-220! www.globenewswire.com/news-release...

submitted 53 days ago • 1 comment

I am excited to report the preprint of my postdoc work in the @olzmannlab.bsky.social! We have discovered the first lipid droplet quality control pathway with broad implications for lipid physiology and diseases associated with LD accumulation and oxidative stress! #lipidtime shorturl.at/2HqFd

submitted 54 days ago • 6 comments